It seems difficult to find any stakeholders in the orphan drug industry favorable to eliminating the fiscal incentives for orphan drug development. And that includes …
-
-
Choosing the Right Channel Strategy for Specialty Product Success
-
[Whitepaper] Challenging Conventional Patient Recruitment and Care Strategies for Rare Disease Studies
-
[[whitepaper]] The New Reality: Maximizing Value in Rare Disease Launches
-
What’s New in Rare Cancer Research? (Spoiler Alert: A Lot!)
-
Accelerating Commercialization of Rare Disease Treatments
